{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Exploratory Endpoint for MRD', 'negativity testing clarified', 'Clarification on how analyses', 'will be performed', 'Section 5 Study Design', 'Study Schema revised to remove', 'Lyophilized cohort will not open', 'description of start of lyophilized', 'until the drug configuration is', 'cohort.', 'available and the enrollment is', 'complete under the frozen', 'configuration.', 'Section 5.5 Dose', 'Added CTCAE grading', 'Aligned with Section 3.4.2 to', 'Justification', 'clarify that the CTCAE scale', 'was utilized in the FTIH study', 'Section 6.1 Inclusion', 'Changed i.e. to e.g. for prior lines', 'Clarification and Prior Lines of', 'Criteria', 'Table 9 footnote cross-reference', 'therapy updated to clarify it is', 'corrected', 'any proteasome inhibitor or', 'IMiD.', 'Section 6.2 Exclusion', 'Systemic anti-myeloma therapy', 'Exclusion Criteria #1 -', 'Criteria', 'clarified as excluded if administered', 'Clarification of timeframe', 'within 14 days or 5 half-lives,', 'required from last treatment of', 'whichever is shorter', 'systemic anti-myeloma therapy', 'Added Exclusion criteria #2 for high', 'dose steroids', 'Exclusion Criteria #2 added to', 'Modified Exclusion criteria #12 to', 'define high dose steroid usage', 'accept malignancy of non-melanoma', 'that may have anti myeloma', 'skin cancers', 'activity though not given to treat', 'the disease', 'QTcF increase to 480 msec from 470', 'msec', 'Exclusion Criteria #13 - QTcF', 'increased to align with GSK', 'internal standards for oncology', 'trials determined by GSK', 'Cardiac Safety Panel.', 'Section 7 Treatments', 'Removed Infusion Time', 'Administrative change', '139']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 7.2 Dose', 'Table edited for clarity.', 'Changes to dose modifications', 'Modifications, Table 13', 'GSK Scale for corneal events', 'guidelines for GSK2857916', 'Dose Modification', 'related Corneal Events further', 'incorporated and Dosing modifications', 'Guidelines for', 'amended', 'clarify dose modifications based', 'GSK2857916', 'on the visual acuity or findings', 'Treatment-Related', 'on ophthalmic examination', 'Corneal Events', 'Section 7.2.2 Dose', 'Dosing delay and restarting language', 'Updated to allow for restart prior', 'Reductions for Toxicity', 'added', 'to next cycle in cases where the', 'treating physician feels it is', 'necessary for participants well-', 'being.', 'Section 7.2.3 Corneal', 'Clarified that corneal supportive care is', 'To provide consistency and', 'Supportive Care', 'based on GSK Corneal Scale (Table', 'alignment throughout the', 'Guidelines', '22)', 'protocol.', 'Section 7.7.2 Prohibited', 'Caution statement for CYP', 'For alignment with IB version', 'Medications', 'inhibitors/inducers added', '05, Section 6.4', 'Section 7.8 Treatment', 'Cross-reference corrected from Table 1', 'Administrative change', 'after the End of Study', 'to Table 3', 'Section 8.1', 'Pregnancy added to the list of reasons', 'To align with Section 9.2.8 and', 'Discontinuation of Study', 'for discontinuation', 'Appendix 5 as animal', 'Treatment', 'reproductive studies have not', 'been conducted with', 'GSK2857916', 'Section 8.2.5 Corneal', 'Added Clarity on use of GSK scale and', 'Alignment throughout protocol.', 'Event Stopping Criteria', 'CTCAE scale for reporting purposes', 'Both the CTCAE and GSK', 'and dose modifications.', 'Scale are to be utilized for', 'reporting of corneal events and', 'clarify that the GSK scale to be', 'utilized for dose modification', 'decisions.', 'Section 9 Study', 'On study visits and PFS follow-up visits', 'Alignment with Section 2,', 'Assessments and', 'separated to aligned with SOA Tables', 'Schedule of Activities', 'Procedures', 'Table 14 - addition of spot urine', 'instructions; and clarification of FISH', 'results to align with Section 2,', 'Schedule of activities', '140']\n\n###\n\n", "completion": "END"}